225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
New solvent-free micronization technology expanded at the Darmstadt site in Germany
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
